Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a huma… Read more
Spyre Therapeutics Inc. (SYRE) - Net Assets
Latest net assets as of September 2025: $455.10 Million USD
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has net assets worth $455.10 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($504.60 Million) and total liabilities ($49.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $455.10 Million |
| % of Total Assets | 90.19% |
| Annual Growth Rate | 58.85% |
| 5-Year Change | 270.3% |
| 10-Year Change | 1334.2% |
| Growth Volatility | 519.51 |
Spyre Therapeutics Inc. - Net Assets Trend (2013–2024)
This chart illustrates how Spyre Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Spyre Therapeutics Inc. (2013–2024)
The table below shows the annual net assets of Spyre Therapeutics Inc. from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $517.80 Million | +181.39% |
| 2023-12-31 | $184.02 Million | +265.80% |
| 2022-12-31 | $50.30 Million | -40.07% |
| 2021-12-31 | $83.94 Million | -39.97% |
| 2020-12-31 | $139.83 Million | +132.74% |
| 2019-12-31 | $60.08 Million | -10.90% |
| 2018-12-31 | $67.43 Million | +33.95% |
| 2017-12-31 | $50.34 Million | -20.06% |
| 2016-12-31 | $62.97 Million | +74.40% |
| 2015-12-31 | $36.10 Million | +1828.63% |
| 2014-12-31 | $1.87 Million | -41.22% |
| 2013-12-31 | $3.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Spyre Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 97049500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.00% |
| Other Comprehensive Income | $180.00K | 0.03% |
| Other Components | $1.49 Billion | 287.76% |
| Total Equity | $517.80 Million | 100.00% |
Spyre Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Spyre Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PROMOTORA OPER (AKY.SG)
STU:AKY
|
$2.84 Billion |
|
Whirlpool Corporation
NYSE:WHR
|
$2.84 Billion |
|
LG Uplus
KO:032640
|
$2.84 Billion |
|
ALMONTY INDUSTRIES CDIS/1
F:ALI0
|
$2.85 Billion |
|
Sealand Securities Co Ltd
SHE:000750
|
$2.84 Billion |
|
Meiko Electronics Co. Ltd
F:MEC
|
$2.84 Billion |
|
Guaranty Trust Holding Co. PLC GDR
LSE:GTCO
|
$2.84 Billion |
|
Chemours Co
NYSE:CC
|
$2.84 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Spyre Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 184,016,000 to 517,804,000, a change of 333,788,000 (181.4%).
- Net loss of 208,018,000 reduced equity.
- New share issuances of 405,232,000 increased equity.
- Other comprehensive income decreased equity by 122,000.
- Other factors increased equity by 136,696,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-208.02 Million | -40.17% |
| Share Issuances | $405.23 Million | +78.26% |
| Other Comprehensive Income | $-122.00K | -0.02% |
| Other Changes | $136.70 Million | +26.4% |
| Total Change | $- | 181.39% |
Book Value vs Market Value Analysis
This analysis compares Spyre Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.85x to 3.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $3.42 | $43.95 | x |
| 2015-12-31 | $78.97 | $43.95 | x |
| 2016-12-31 | $160.76 | $43.95 | x |
| 2017-12-31 | $83.18 | $43.95 | x |
| 2018-12-31 | $80.96 | $43.95 | x |
| 2019-12-31 | $47.01 | $43.95 | x |
| 2020-12-31 | $65.50 | $43.95 | x |
| 2021-12-31 | $31.92 | $43.95 | x |
| 2022-12-31 | $14.92 | $43.95 | x |
| 2023-12-31 | $26.68 | $43.95 | x |
| 2024-12-31 | $11.01 | $43.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Spyre Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23478.33%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (-40.17%) is above the historical average (-126.88%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -552.72% | 0.00% | 0.00x | 1.57x | $-10.53 Million |
| 2015 | -31.28% | -185.62% | 0.16x | 1.07x | $-14.91 Million |
| 2016 | -34.46% | -468.84% | 0.07x | 1.07x | $-27.99 Million |
| 2017 | -54.11% | -523.27% | 0.09x | 1.11x | $-32.27 Million |
| 2018 | -65.77% | -1140.64% | 0.05x | 1.15x | $-51.09 Million |
| 2019 | -130.25% | 0.00% | 0.00x | 1.38x | $-84.26 Million |
| 2020 | -57.85% | 0.00% | 0.00x | 1.16x | $-94.88 Million |
| 2021 | -78.39% | -351.14% | 0.17x | 1.31x | $-74.20 Million |
| 2022 | -166.61% | -3598.75% | 0.03x | 1.41x | $-88.85 Million |
| 2023 | -184.11% | -38238.15% | 0.00x | 1.86x | $-357.19 Million |
| 2024 | -40.17% | -23478.33% | 0.00x | 1.18x | $-259.80 Million |
Industry Comparison
This section compares Spyre Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Spyre Therapeutics Inc. (SYRE) | $455.10 Million | -552.72% | 0.11x | $2.84 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |